Biopolym. Cell. 1989; 5(2):5-16.
http://dx.doi.org/10.7124/bc.0000A0
Discussions
Objectives and problems of gene therapy
1Kordium V. A.
  1. Institute of Molecular Biology and Genetics, Academy of Sciences of the Ukrainian SSR
    Kiev, USSR

Abstract

A range of problems comprising the notion «gene therapy» in the broad and narrow sense has been analyzed. In the broad sense this field of research includes the following components: gene surgery, gene therapy itself; gene prophylaxis, gene diagnosis, gene vaccination, «gene antihumanism», gene engineering of gametogenesis, gametes and zygotes and prenatal gene engineering. Taking into account the components and the range of problems solved by them, the full definition of the field of research has been suggested as well. In its full meaning gene therapy signifies genome identification per individuum followed by correction of hereditary cell apparatus of the whole organism or its separate tissues, elimination of diseases inherent in the patient and prevention of appearance of any novel pathologies with time and in accordance with desire (or in case of need) reconstruction (in human cells) of novel genetic information ensuring the emergence of potentially different phenotypes up to those completely absent in nature in the living and future generations.
Full text: (PDF, in Russian)

References

[1] Edwards RG. Causes of early embryonic loss in human pregnancy. Hum Reprod. 1986;1(3):185-98.
[2] Galjaard H. Biochemical diagnosis of genetic disease. Experientia. 1986;42(10):1075-85.
[3] Neri G. Malformazioni fetali da alterazioni dell'assetto genico o cromosomico. Acta med rom. 1986; 24(4):403-5.
[4] Hollister D, Krane S, Myers J et al. Genetic diseases. Gene families collagen and other proteins. New York etc., 1980:191-202.
[5] US blood resources: an industry in crisis. Biotechnol. Bull. 1987; 6(2):5.
[6] Stoltz J. F. Transfusion sanguine et biotechnologie. Rev ing. 1985; 38(296):31-32.
[7] Cancer drug delivery deal for Cetus. Pract Biotechnol. 1986; 7(6):8.
[8] Strongin AYa, Borukhov SI, Bogush VG, Aleksenko AP, Kostrov SV, Novikov AA, Ryzhavskaya AS, Izotova LS. Natural and genetically engineered proteins - similarities and differences. Biotekhnologiya. 1987; 3(3):325-31.
[9] Yanchinski S. Boom and bust in the bio business. New Sci. 1987; 113(1544):44-7.
[10] Choudary PV, Barranger JA, Tsuji S, Mayor J, LaMarca ME, Cepko CL, Mulligan RC, Ginns EI. Retrovirus-mediated transfer of the human glucocerebrosidase gene to Gaucher fibroblasts. Mol Biol Med. 1986;3(3):293-9.
[11] Friedmann T. HPRT Gene Transfer as a Model for Gene Therapy. Genet Eng. 1985;263–82.
[12] Garver RI Jr, Chytil A, Karlsson S, Fells GA, Brantly ML, Courtney M, Kantoff PW, Nienhuis AW, Anderson WF, Crystal RG. Production of glycosylated physiologically "normal" human alpha 1-antitrypsin by mouse fibroblasts modified by insertion of a human alpha 1-antitrypsin cDNA using a retroviral vector. Proc Natl Acad Sci U S A. 1987;84(4):1050-4.
[13] Ishizaki K, Tsujimura T, Yawata H, Fujio C, Nakabeppu Y, Sekiguchi M, Ikenaga M. Transfer of the E. coli O6-methylguanine methyltransferase gene into repair-deficient human cells and restoration of cellular resistance to N-methyl-N'-nitro-N-nitrosoguanidine. Mutat Res. 1986;166(2):135-41.
[14] Jolly DJ, Willis RC, Friedmann T. Variable stability of a selectable provirus after retroviral vector gene transfer into human cells. Mol Cell Biol. 1986;6(4):1141-7.
[15] Kataoka H, Hall J, Karran P. Complementation of sensitivity to alkylating agents in Escherichia coli and Chinese hamster ovary cells by expression of a cloned bacterial DNA repair gene. EMBO J. 1986;5(12):3195-200.
[16] Ledley FD, Woo SL. Molecular basis of alpha 1-antitrypsin deficiency and its potential therapy by gene transfer. J Inherit Metab Dis. 1986;9 Suppl 1:85-91.
[17] Limf B, Williams DA, Mulligan R, Orkin SI. Human adenosine deaminase (ADA) expression in murine hematopoietic progenitors and CFU-S infected with simplified retroviruses. Am J Hum Genet. 1986; 39(3):A209.
[18] Malissen B. Transfer and expression of MHC genes. Immunol Today. 1986;7(4):106–12.
[19] Miesfeld R, Rusconi S, Godowski PJ, Maler BA, Okret S, Wikström AC, Gustafsson JA, Yamamoto KR. Genetic complementation of a glucocorticoid receptor deficiency by expression of cloned receptor cDNA. Cell. 1986;46(3):389-99.
[20] Palmer TD, Hock RA, Osborne WR, Miller AD. Efficient retrovirus-mediated transfer and expression of a human adenosine deaminase gene in diploid skin fibroblasts from an adenosine deaminase-deficient human. Proc Natl Acad Sci U S A. 1987;84(4):1055-9.
[21] Shimizu Y, Koller B, Geraghty D, Orr H, Shaw S, Kavathas P, DeMars R. Transfer of cloned human class I major histocompatibility complex genes into HLA mutant human lymphoblastoid cells. Mol Cell Biol. 1986;6(4):1074-87.
[22] Sorge J, Kuhl W, West C, Beutler E. Complete correction of the enzymatic defect of type I Gaucher disease fibroblasts by retroviral-mediated gene transfer. Proc Natl Acad Sci U S A. 1987;84(4):906-9.
[23] Valerie K, de Riel JK, Henderson EE. Genetic complementation of UV-induced DNA repair in Chinese hamster ovary cells by the denV gene of phage T4. Proc Natl Acad Sci U S A. 1985;82(22):7656-60.
[24] Wood PA, Chao IC, Baudet AL, O'Brein WE. Retrovirus mediated gene transfer of argininosuccinate synthetase (AS) into cultured rodent cells and human fibroblasts from citrullinemic patients. Ame J Hum Genet. 1986; 39(3):A226.
[25] Zdzienicka MZ, Roza L, Westerveld A, Bootsma D, Simons JW. Biological and biochemical consequences of the human ERCC-1 repair gene after transfection into a repair-deficient CHO cell line. Mutat Res. 1987;183(1):69-74.
[26] Belmont JW, Henkel-Tigges J, Wager-Smith K, Chang SM, Caskey CT. Towards gene therapy for adenosine deaminase deficiency. Ann Clin Res. 1986;18(5-6):322-6.
[27] Williams DA, Orkin SH, Mulligan RC. Retrovirus-mediated transfer of human adenosine deaminase gene sequences into cells in culture and into murine hematopoietic cells in vivo. Proc Natl Acad Sci U S A. 1986;83(8):2566-70.
[28] Kuehn MR, Bradley A, Robertson EJ, Evans MJ. A potential animal model for Lesch-Nyhan syndrome through introduction of HPRT mutations into mice. Nature. 1987 Mar 19-25;326(6110):295-8.
[29] Miller JA. Interspecies gene-transfer ban rejected. Sci News. 1984;126(18):278.
[30] Muller H. Human gene therapy: possibilities and limitations. Experientia. 1987;43(4):375-8.
[31] Costantini F, Chada K, Magram J. Correction of murine beta-thalassemia by gene transfer into the germ line. Science. 1986;233(4769):1192-4.
[32] Rubin EM, Lu RH, Cooper S, Kan YW. A mouse model for sickle cell anemia. Am J Hum Genet. 1986; 39(3):A216.
[33] Sifers RN, Carlson JA, Clift SM, DeMayo FJ, Bullock DW, Woo SL. Tissue specific expression of the human alpha-1-antitrypsin gene in transgenic mice. Nucleic Acids Res. 1987;15(4):1459-75.
[34] Robertson E, Bradley A, Kuehn M, Evans M. Germ-line transmission of genes introduced into cultured pluripotential cells by retroviral vector. Nature. 1986 Oct 2-8;323(6087):445-8.
[35] Wade N. UCLA gene therapy racked by friendly fire. Science. 1980;210(4469):509-11.
[36] Joyce C. US approves gene therapy on humans. New Sci. 1985;108(1476):19.
[37] Milewski EA. Discussions on human gene therapy. Recomb DNA Tech Bull. 1986;9(2):88-130.
[38] Friedmann T. Models for human gene therapy. Biotechnol. diagn.: proc. Int. symp unpact biotechnol. diagn. (Rome, Apr. 16-18). Amsterdam etc., 1985:309
[39] Delehanty J, White RL, Mendelsohn ML. International Commission for Protection Against Environmental Mutagens and Carcinogens. ICPEMC Meeting Report No. 2. Approaches to determining mutation rates in human DNA. Mutat Res. 1986;167(3):215-32.
[40] Gall J. G. Human genome sequencing. Science. 1986. 233, N 4771:1367- 1368.
[41] Guttler F. Diagnosis of inherited metabolic disorders by DNA analysis. Med Lab Sci. 1985;42(4):326-32.
[42] Vilenchik MM. Biological basis of aging and longevity. Moscow, Znanie, 1980; 224 p.
[43] Meheus LCoomans A. Het probleem van veroudering: een overzicht van de voornaamste theorieen en de stand van het onderzoek. Acad, analecta. 1986. 48(3):61-77.
[44] Schwartz F. W. Lebenswartung - Morbiditat - Mortalitat. Demographische Entwick- 15. Iungstrends und Konsequenzen fiir die arztlichen Aufgaben. Miinchen med. Wochenschr. 1986. 128, N 5. S. 68-72.
[45] Three research groups produce DNA probes for cystic fibrosis. Drug Hicense Opport. 1985;12:55.
[46] Atlan H. Biotechnologies, homme et nature. Futuribles. 1987;108:7-25.
[47] Gazarian KG, Nabirochkin SD, Nabirochkina EN, Tatosian AG, Ambartsumian NS. Induction of unstable mutations in Drosophila melanogaster by microinjection of DNA from oncogenic viruses into the embryo polar plasma. II. Analysis of the role of injected DNA. Genetika. 1987;23(2):214-27.
[48] Nabirochkin SD, Nabirochkina EN, Gazarian KG. Induction of unstable mutations in Drosophila melanogaster by microinjection of DNA from oncogenic viruses into the embryo polar plasma. I. Effect of the embryo genotype. Genetika. 1987;23(2):202-13.
[49] Emerman M, Temin HM. Comparison of promoter suppression in avian and murine retrovirus vectors. Nucleic Acids Res. 1986;14(23):9381-96.
[50] Gélinas C, Temin HM. Nondefective spleen necrosis virus-derived vectors define the upper size limit for packaging reticuloendotheliosis viruses. Proc Natl Acad Sci U S A. 1986;83(23):9211-5.
[51] Rhode BW, Emerman M, Temin HM. Instability of large direct repeats in retrovirus vectors. J Virol. 1987;61(3):925-7.
[52] Brandt CR, Buonaguro FM, McDougall JK, Galloway DA. Plasmid mediated mutagenesis of a cellular gene in transfected eukaryotic cells. Nucleic Acids Res. 1987;15(2):561-73.
[53] Dougherty JP, Temin HM. High mutation rate of a spleen necrosis virus-based retrovirus vector. Mol Cell Biol. 1986;6(12):4387-95.
[54] Gebara MM, Drevon C, Harcourt SA, Steingrimsdottir H, James MR, Burke JF, Arlett CF, Lehmann AR. Inactivation of a transfected gene in human fibroblasts can occur by deletion, amplification, phenotypic switching, or methylation. Mol Cell Biol. 1987;7(4):1459-64.